Despite the availability of treatments to mitigate some of the most prevalent disease- driving processes, including intraocular pressure reduction in patients with glaucoma or anti-VEGF therapy in patients with neovascular age-related macular degeneration, many patients experience continued neuronal death and vision loss even during seemingly adequate treatment. This evidence concerns the gene VEGFA and wet macular degeneration.